VanEck Associates
RXST icon

VanEck Associates’s RxSight RXST Stock Holding History

VanEck Associates’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-85
Closed -$1K – 1486
2025
Q3 		$1K Hold
85
– – ﹤0.01% 1425
2025
Q2 		$1K Sell
85
-4,396
-98% -$66.1K ﹤0.01% 1392
2025
Q1 		$113K Buy
4,481
+1,216
+37% +$36.1K ﹤0.01% 1270
2024
Q4 		$112K Buy
3,265
+1,040
+47% +$46.9K ﹤0.01% 1266
2024
Q3 		$108K Sell
2,225
-158
-7% -$8.1K ﹤0.01% 1248
2024
Q2 		$143K Sell
2,383
-195
-8% -$11.1K ﹤0.01% 1224
2024
Q1 		$133K Buy
+2,578
New +$127K ﹤0.01% 1220

Other funds holding RXST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VanEck Associates's RXST Position: Q4 2025 in Review

VanEck Associates sold out of RxSight (RXST) in Q4 2025, closing a stake of 85 shares — an estimated $1K sold.

VanEck Associates first reported a position in RXST in Q1 2024 and held it in 7 quarters. The position peaked at $143K in Q2 2024. 163 funds tracked by Wall St. Rank hold RXST as of Q4 2025.

  • VanEck Associates reported no remaining RxSight position as of Q4 2025 after selling out during the quarter.
  • VanEck Associates sold 85 RxSight shares in Q4 2025, an estimated $1K.
  • VanEck Associates first reported a position in RxSight in Q1 2024 and held it in 7 quarters.
  • VanEck Associates's RxSight position peaked at $143K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held RxSight as of Q4 2025.

Based on VanEck Associates's 13F filing for Q4 2025, filed 13 Feb 2026.